COMPASS Pathways plc (NASDAQ: CMPS) saw its shares surge 6.72% in pre-market trading following the release of its first-quarter 2026 financial results and positive business updates.

The biotechnology company reported a quarterly loss per share of $(0.30), beating the analyst consensus estimate of $(0.34). Operating income also surpassed expectations, coming in at a loss of $42.904 million versus an estimated loss of $47.1 million. Net income for the quarter was $91.2 million, significantly aided by a non-cash gain related to warrant fair value adjustments. The company ended the quarter with a strong cash position of $466 million, which it expects to fund operations into 2028.

Investor sentiment was further buoyed by significant regulatory advancements for the company's lead investigational treatment, COMP360 (synthetic psilocybin) for treatment-resistant depression. The U.S. Food and Drug Administration (FDA) has granted a rolling New Drug Application (NDA) submission and review request based on positive Phase 3 data. Furthermore, the award of a Commissioner's National Priority Review Voucher (CNPV) has the potential to accelerate the FDA review timeline. The company remains on track for a final NDA submission in the fourth quarter of 2026, with commercial launch readiness targeted by the end of the year.